claim: differences between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with covid-19 pneumonia and acute respiratory distress syndrome
evidence_1: conclusion: this proof-of-concept study may support the rationale of use of colchicine for the treatment of covid-19.